Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, CXP

BioDuro Completes Acquisition of Molecular Response to Accelerate Translational Oncology Capabilities


SAN DIEGO, March 5, 2018 /PRNewswire/ -- BioDuro LLC, a leading global life sciences contract research and development organization, announced today the acquisition of Molecular Response LLC and its world-class translational oncology research platform, including its biobank of >100,000 viable tumor specimens. BioDuro customers can now access this platform to support a range of drug discovery oncology and immunooncology studies--from immunophenotyping screens to xenograft pharmacology studies.

The Molecular Response oncology platform comprises the world's largest collection of viable tumor specimens.  These specimens maintain the complexity and heterogeneity of the patient cancer, including tumor, immune and stromal cells, enabling large-scale in vitro and in vivo studies that are otherwise impossible to perform.

"We are committed to growing BioDuro into a complete chemistry and biology provider for our clients, and unique platforms in oncology are a critical centerpiece of that strategy," said TJ Deng, General Manager for BioDuro Discovery.  "The Molecular Response acquisition immediately strengthens our capability and provides our clients a continuous set of capability, enabling our customers to start with our chemistry services through preclinical and translational oncology studies, all the way to IND."

BioDuro biology maintains a state-of-the-art in vivo oncology capability, including 18,000 sq ft AAALAC accredited vivarium, cell-derived xenograft (CDX), patient-derived xenograft (PDX), and syngeneic oncology models, with animal imaging and multi-color flow cytometry for immune cell analysis.  BioDuro recently launched hTME-3DX Screen and Verify, providing a combination of humanized 3D tumor models in vitro, and follow-on in vivo PDX capability, matched to same primary patient sample.

As part of the acquisition, Molecular Response CEO, Thomas B. Broudy, PhD will assume the role of Executive Vice President, Translational Sciences & Strategy.

"The combination of operational scale and platform depth allows our partners to investigate a virtually unlimited number of drug discovery programs?from targeting T-cell checkpoint biology to defining biomarkers predictive of response," said Broudy.  "The platform has been validated through hundreds of pharma and biotech preclinical and translational oncology research studies, and we are now excited to support BioDuro global customers with this world-class set of solutions."

BioDuro will maintain Molecular Response as a wholly-owned subsidiary, growing its ongoing operations in Shanghai, Beijing and San Diego with new service offerings using the biobank platform.  Molecular Response will continue all business development efforts to sell biospecimens to strategic partners interested in tissue acquisition to support internal capabilities.

About BioDuro
BioDuro is a leading, global life sciences research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery services spanning target identification to IND filing, through to GMP manufacture of drug substance for clinical trials. With depth and breadth of therapeutic expertise in small and large molecule discovery, development and scale up, combined with unique technology platforms such as high content 3D drug screening and bioavailability enhancement of insoluble compounds, BioDuro is well positioned to help biopharmaceutical partners significantly accelerate their lead discovery programs, and de-risk development programs for higher value outcomes. Visit www.bioduro.com

 

SOURCE BioDuro LLC


These press releases may also interest you

at 13:05
Regulatory News: MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported...

at 13:00
The following is written by Dr. Steven Gonzales, Chancellor, Maricopa Community Colleges, a member of the American Association of Community Colleges: Arizona, like many states across America, is facing a nurse shortage.  The pandemic has taken a toll...

at 12:55
Breckenridge Brewery ("Breckenridge" or the "Brewery"), a pioneer in Colorado's craft beer scene, and a subsidiary of Tilray Brands, Inc. ("Tilray" or the "Company") , announced today an exciting partnership with the Denver Nuggets to launch a...

at 12:46
Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today a milestone for its iTindtm device with its availability and greater patient access through the largest healthcare group...

at 12:46
Amid the demands of dentistry, where resilience is paramount, practitioners confront challenges beyond clinical skills alone. Thriving in this environment requires a particular mindset, enabling professionals to adeptly navigate pressures, maintain...

at 12:45
The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering. The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of...



News published on and distributed by: